|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 14, 2017 ) Publisher's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.
This report provides information on the therapeutic development based on PD-1 and PD-L1 Inhibitors mechanism of action dealing with around 20+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Publisher's Report also assesses the PD-1 and PD-L1 Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.
For more information about this report: http://www.reportsweb.com/pd-1-and-pd-l1-inhibitors-2017
Report Scope
- The report provides competitive pipeline landscape of PD-1 and PD-L1 Inhibitors
- The report provides the marketed drugs information including its sales, development activities and details of patent expiry
- The report provides the insight of current and future market for PD and PD-L1 inhibitors
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the PD-1 and PD-L1 Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for PD-1 and PD-L1 Inhibitors and also provide company profiling
- The report also gives the information of dormant pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001608699/sample
Reasons to Buy
- Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
- Complete MOA intelligence and complete understanding over therapeutics development for PD-1 and PD-L1 Inhibitors
- Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
- Devise corrective measures for pipeline projects by understanding PD-1 and PD-L1 Inhibitors pipeline depth and focus of Indication therapeutics
- Developing strategic initiatives to support your drug development activities.
- Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
- Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
- Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions
Table of Contents
Introduction
Executive Summary
Programmed Death 1 (PD-1)
Programmed Death Ligand 1 (PD-L1)
Role of PD-1 and PD-L1 pathways
MOA of PD-1 and PD-L1 inhibitors
Significance of PD-1 and PD-L1 inhibitors
PD-1 and PD-L1 Active Therapy Areas & Epidemiology
Metastatic Renal Cell Carcinoma
Squamous Cell Carcinomas of the Head and Neck
Metastatic Colorectal Cancer
Non-Small Cell lung cancer
Biomarkers - PD-1 and PD-L1 inhibitors
Market Overview
Comparative Analysis of Pipeline &Marketed Drugs
Marketed Product of PD-1 and PD-L1 drugs -Overview
Marketed Drug Candidate Profiles
Pembrolizumab
Nivolumab
Atezolizumab
Marketed Drugs Sales
Details of Patent Expiry of Marketed Drugs
Current and Future Market for PD and PD-L1 inhibitors
Challenges and Barriers associated with use of PD and PD-L1 inhibitors
PD-1/PD-L1Combinations Creating Boom
Pipeline Therapeutics
An overview of pipeline products
Pipeline Therapeutics Overview
Therapeutics under Development by MOA
Therapeutics under Development by Companies
Last Stage Products (Phase III and Filed)
Comparative Analysis
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Unknown Stages Molecules
Therapeutic Assessment of pipeline
Therapeutics under Development by Product Type
Therapeutics under Development by Phase for Monotherapy
Therapeutics under Development by Phase for Combination therapy
Therapeutics under Development by Molecule Type
Assessment by Stage and Molecule Type
Therapeutics under Development by Route of Administration
Assessment by Stage and Route of Administration
Dormant Products
Comparative Analysis
SWOT Analysis
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001608699/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
